Real-world outcomes with NINLARO® (ixazomib) + Rd

A video on the key strengths and limitations of RCTs and RWE studies plus real-world support for the effectiveness of NINLARO plus lenalidomide and dexamethasone (NRd) in patients with RRMM.

The efficacy of NRd in treating patients with RRMM has been established in the RCT setting.¹ RCTs aim to assess the efficacy of therapeutic interventions through key clinical endpoints, remaining the gold standard for therapeutic evaluation and regulatory decision-making.² RWE studies investigate the performance of an intervention under real-world conditions³ by providing additional insights not addressed by RCTs, such as long-term effectiveness and safety data^4,5 and treatment outcomes in typically underrepresented patient groups. RWE studies are increasing in relevance, and they can serve to complement clinical data.^3-8

Associate Professor Karthik Ramasamy (Oxford University Hospitals NHS Trust) discusses this topic in the video above.

We have also developed a summary of the data explained in the video, this can be accessed below.

View the guide here

Please note, this is to be viewed online only. Not to be downloaded or printed.

If you would like to discuss this content with a Takeda representative, please click here. 

NINLARO® (ixazomib) in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.⁹

NRd, NINLARO + lenalidomide + dexamethasone; RCT, randomised control trial; RRMM, relapsed/refractory multiple myeloma; RWE, real-world evidence.             
1. Moreau P et al. N Engl J Med 2016;374:1621–1634; 2. Derman BA et al. Blood Rev 2022;53:100913; 3. Blonde L et al. Adv Ther 2018;35:1763–1774; 4. Chodankar D. Perspect Clin Res 2021;12:171–174; 5. Camm AJ and Fox KAA. Open Heart 2018;5:e000788; 6. Roberts MH and Ferguson GT. Pharmacoecon Open 2021;5:3–11; 7. Richardson PG et al. Blood Cancer J 2018;8:109; 8. Katkade VB et al. J Multidiscip Health 2018;11:295–304; 9. NINLARO. Summary of Product Characteristics.